A Dickensian Reality: Warfarin Patients Are Treated Like Orphans – Says Pall Onundarson
Pall Onundarson, Professor Emeritus at Landspitali University Hospital, posted on LinkedIn:
”I recently read eye-opening books by Chris Deacon, Jerry Avorn, and John Abramson on corruption in increasingly corporate-driven healthcare systems. This reading makes one point unmistakably clear: advances in health technology now depend largely on a manufacturer’s ability to profit. Improvements to older technologies are suppressed – as though they do not exist – even when patients who could greatly benefit remain. These patients are simply left behind, and regulators make no demands on their behalf.
As the reader may guess, I am referring to patients who still need warfarin (or other VKAs) because newer agents are unsuitable for them. They find themselves in a situation reminiscent of a hungry Oliver Twist in a 19th-century English orphanage pleading, “Please, Sir, I want some more.” These patients are deliberately treated in a Dickensian manner – as burdensome orphans who deserve only minimal servings and no advances.
By 2025, it has become clear that conventionally PT-INR monitored warfarin and other VKAs are still the most effective oral anticoagulants for the most severe thromboembolic conditions (MHV, RHD, APLAS, frail AF, and possibly others). But warfarin management can be made more convenient and outcomes improved. Why, then, are highly effective advances in VKA care met with silence from the owners of the orphanage and their acolytes? Why are the orphans and their caretakers not informed about meaningful improvements, such as more stable or enhanced VKAs? Is it possible that those who profit most simply do not want warfarin management to improve in needy patients?
Early in my career, I believed medicine was guided by well-meaning fiduciaries committed to reducing disability and death. Later, I realized that progress is now permitted mainly when corporate shareholders can maximize profit. Corporations promote newer drugs sold at high prices as being superior to older generics while blocking inexpensive advances that could improve outcomes with those older medications. They appear untroubled if this sacrifices some of the orphans who must still rely on drugs like warfarin – drugs whose management remains suboptimal because meaningful improvements have been suppressed. In this way, the orphans are denied effective, simple, and cost-saving innovations, even at the cost of greater disability and death.”
Keep up with Hemostasis Today.
-
Oct 22, 2026, 18:04Basem Goueli: Blood Clots in the NFL
-
Oct 22, 2026, 17:57Syed Ahmed: Viral Triggers of Immune Thrombocytopenia and Thrombosis
-
Oct 22, 2026, 17:49Valerie Tutwiler: Bridging Engineering and Medicine to Advance Thrombosis Research
-
Oct 22, 2026, 17:41Jesus Ardila Novoa: How Patient Education Can Transform Hemophilia Care
-
Oct 22, 2026, 17:30Filipe Gonçalves: Advancing Bleeding Disorder Diagnosis Through Multidisciplinary Collaboration
-
Oct 22, 2026, 17:17Storage Pool Deficiency An Overview of a Rare Platelet Disorder – EHC
-
Oct 22, 2026, 17:10Matthew Hazell: Optimizing the Use of Rare Red Blood Cell Units
-
Oct 22, 2026, 17:03Smita Patil: New Insights Into Platelet Alpha-Granule Secretion
-
Oct 22, 2026, 16:48Ahmed Alotaibi: Rare Rh Phenotype and Severe Fetal Anaemia